ALK-IN-21

Cat. No.:	HY-146408
CAS No.:	2901889-01-6
Molecular Formula:	$C_{35}H_{45}ClN_6O_6S_4$
Molecular Weight:	809.48
Target:	Anaplastic lymphoma kinase (ALK)
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	ALK-IN-21 (Compound B10), a potent ALK inhibitor for ALKG1202R mutation, exhibits remarkable enzymatic inhibitory potency with IC_{50} values of 4.59 nM, 2.07 nM and 5.95 nM toward ALK^{WT}, ALK^{L1196M} and ALK^{G1202R}, respectively. ALK-IN-21 efficiently inhibits the proliferation of ALK-positive Karpas299 and H2228 cells both with IC_{50} values of 0.07 μM. ALK-IN-21 can be used for the research of anaplastic large cell lymphoma[1].
IC_{50} & Target	IC_{50}: 2.07 nM (ALK^{L1196M}), 4.59 nM (ALK^{WT}), 5.95 nM (ALK^{G1202R})[1]
In Vitro	ALK-IN-21 (Compound B10) inhibits the proliferation of Karpas299, H2228 and HCT116 cells with IC_{50} values of 0.07, 0.07 and 5.53 μM, respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Xinyue Wang, et al. Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel ALK inhibitors. Bioorg Med Chem. 2022 Jul 15;66:116794.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA